Latest News Archive

Please select Category, Year, and then Month to display items

Prof Peter Rosseel delivers guest lecture during UFS visit

13 August 2024 | Story Anthony Mthembu | Photo Sibahle Dayimani and Amandla Kulu

The Business School at the University of the Free State (UFS) hosted Prof Peter Rosseel, Managing Director of Management Consulting and Research – a spin-off of the Catholic University of Leuven in Belgium – for a guest lecture during his visit to the UFS Faculty of Economic and Management Sciences (EMS).

The guest lecture took place on 19 July 2024 in the Business School Auditorium and was attended by academics from the UFS.

Reflecting on the lecture

The lecture presented by Prof Rosseel focused on how combining strategy, strategy implementation, culture transformation, leadership, and learning successfully leads to sustainable growth, creates engagement, and delivers tangible results. Throughout the lecture, Prof Rosseel spoke about how experts tend to make bad leaders and therefore stop change from happening within an organisation. In fact, he highlighted that, “Experts stop change from happening within the workplace because experts, by definition, look through the eyes of their expertise, but you cannot reduce the world to different forms of expertise, as it is holistic.” As such, he argued that to change an organisation, one must see things from the point of view of others.

Furthermore, Prof Rosseel delved deeper into the hierarchical operating model within organisations. He indicated that the above model should be one community within organisations; however, unfortunately it is not. This is because organisations are made up of several departments such as finance and human resources. As such, he regards these departments to be silos that could prove to be detrimental to organisations, as each silo can create its own culture as opposed to an organisational culture. These are some of the points he discussed throughout the lecture.

After the lecture concluded, the audience had the opportunity to engage with Prof Rosseel on his viewpoints. In fact, Lyle Markham, Academic Head of Department and Lecturer in Industrial Psychology at the UFS, was one of the audience members and described the lecture as insightful.

News Archive

Nuclear Medicine on the forefront of cancer research

2017-07-10

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma. The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept